Warrants to purchase common stock
- Symbol
- OABIW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Current Report · Items 5.07 · 8-K
OmniAb, Inc.
OABINASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. OmniAb, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders (the “Annual Meeting”) on June 17, 2026. Set forth below are the final voting results for the actions taken by the shareholders at the Annual Meeting. Proposal 1.…
Company context
OmniAb licenses cutting-edge discovery research technology to the pharmaceutical and biotech industries and academic institutions to enable the discovery of next-generation therapeutics. The Company’s technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. This includes xPloration®, the Company's AI-powered, high-throughput single B-cell screening platform. At the heart of the OmniAb platform is something the Company calls Biological Intelligence™, which powers the immune systems of its proprietary, transgenic animals to create optimized candidates for human therapeutics. The Company primarily derives revenue from license fees for technology access, milestones from partnered programs and service revenue from research programs as well as revenue associated with the xPloration platform.
Current securities
Registered securities in this filing
OMNIAB, INC. · 8-K · Filed 2026-06-18
Common Stock, par value $0.0001 per share
- Symbol
- OABI
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07. Submission of Matters to a Vote of Security Holders.
OmniAb, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders (the “Annual Meeting”) on June 17, 2026. Set forth below are the final voting results for the actions taken by the shareholders at the Annual Meeting.
Proposal 1. The election of two directors to serve as Class I directors for a three-year term to expire at the 2029 Annual Meeting of Shareholders. The following two Class I directors were elected by the votes indicated:
For Withheld Broker Non-Votes
──────────────────────────────────────────────────────────────────────────────────
Jennifer Cochran, Ph. D. 57,948,696 25,997,984 18,464,904
Matthew W. Foehr 82,231,849 1,714,831 18,464,904
Proposal 2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The appointment was ratified by the votes indicated:
For Against Abstain Broker Non-Votes
───────────────────────────────────────────────────────────────
102,163,551 112,653 135,380 0